Hee Jo Baek

Hee Jo Baek

Auto-generated profile, based on publicly available information

Hee Jo Baek

Department of Pediatrics, Chonnam National University Hwasun Hospital, Hwasun-gun 58128, Jeollanam-do, Republic of Korea

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2019 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
THThe Hereditary Hemolytic Anemia Working Party Of The Korean Society Of Hematology
The Hereditary Hemolytic Anemia Working Party Of The Korean Society Of Hematology
HCHyoung Soo Choi
Hyoung Soo Choi
QCQute Choi
Qute Choi
JKJung-Ah Kim
Jung-Ah Kim
KIKyong Ok Im
Kyong Ok Im
DLDong-Soon Lee
Dong-Soon Lee
Current diagnostic tests for hereditary spherocytosis (HS) focus on the detection of hemolysis or indirectly assessing defects of membrane protein, whereas direct methods to detect protein defects are complicated and difficult to implement. In the present study, we investigated the patterns of genetic variation associated with HS among patients clinically diagnosed with HS. Multi-gene targeted sequencing of 43 genes (17 RBC membrane protein-encoding genes, 20 RBC enzyme-encoding genes, and six additional genes for the differential diagnosis) was performed using the Illumina HiSeq platform. Among 59 patients with HS, 50 (84.7%) had one or more significant variants in a RBC membrane protein-encoding genes. A total of 54 significant variants including 46 novel mutations were detected in six RBC membrane protein-encoding genes, with the highest number of variants found in SPTB (n = 28), and followed by ANK1 (n = 19), SLC4A1 (n = 3), SPTA1 (n = 2), EPB41 (n = 1), and EPB42 (n = 1). Concurrent mutations of genes encoding RBC enzymes (ALDOB, GAPDH, and GSR) were detected in three patients. UGT1A1 mutations were present in 24 patients (40.7%). Positive rate of osmotic fragility test was 86.8% among patients harboring HS-related gene mutations. This constitutes the first large-scaled genetic study of Korean patients with HS. We demonstrated that multi-gene target sequencing is sensitive and feasible that can be used as a powerful tool for diagnosing HS. Considering the discrepancies of clinical and molecular diagnoses of HS, our findings suggest that molecular genetic analysis is required for accurate diagnosis of HS.

15 June 2021 in Haemophilia
Verified
Journal Article
Open access
PDF file
YPYoung Shil Park
Young Shil Park
THTai Ju Hwang
Tai Ju Hwang
GCGoon Jae Cho
Goon Jae Cho
SKSoon Ki Kim
Soon Ki Kim
SPSang Kyu Park
Sang Kyu Park
KYKiyoung Yoo
Kiyoung Yoo
Introduction: Reports on patients’ satisfaction and preferred characteristics for treatments would be worthwhile when choosing an optimal treatment reflecting patients’ perspectives.Aim: To identify the characteristics and treatment patterns of patients with haemophilia A, or their caregivers, in Korea and explore patient preferences and satisfaction with their treatment.Methods: This cross‐sectional, multicentre, observational study was conducted from April 2018 to September 2019 at six nationwide hospitals and three Korea Hemophilia Foundation clinics. Patients aged ≥16 years, or legal caregivers of paediatric patients, who had used factor VIII (FVIII) concentrates for ≥1 month were enrolled. Satisfaction with treatment was measured using the Treatment Satisfaction Questionnaire for Medication (TSQM); preference was evaluated using discrete choice experiment (DCE), with 10 series of two hypothetical treatment options created from D‐efficient block design, which varied across five attributes.Results: Overall, 505 patients (mean age 31 years) were enrolled in the study. Patients had received FVIII concentrate for an average of 102.9 months (prophylaxis: 53.5%; on‐demand: 22.2%). Mean TSQM scores were 64.6 (effectiveness domain), 97.9 (side effects), 57.1 (convenience) and 66.8 (global satisfaction). The number of vials per injection, and the frequency of drug administration, was significantly associated with treatment satisfaction. According to DCE, simpler treatment options were preferred by patients/caregivers.Conclusion: The lowest satisfaction levels were shown in the treatment convenience domain. Patients/parents preferred simpler and easier treatment characteristics. In an attempt to enhance the overall satisfaction of patients and caregivers with treatment, consideration of more convenient characteristics is required in future decisions regarding treatment selection.

1 January 2020 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
YSYe Jee Shim
Ye Jee Shim
HJHye Lim Jung
Hye Lim Jung
HSHee Young Shin
Hee Young Shin
HKHyoung Jin Kang
Hyoung Jin Kang
JCJung Yoon Choi
Jung Yoon Choi
THThe Red Blood Cell Disorder Working Party Of The Korean Society Of Hematology
The Red Blood Cell Disorder Working Party Of The Korean Society Of Hematology
Shim YJ, et al. J Korean Med Sci. 2020 Jul;35(33):e279. https://doi.org/10.3346/jkms.2020.35.e279

1 May 2013
Verified
Journal Article
Closed access
HBHee-Jo Baek
Hee-Jo Baek
JKJu-Sun Kim
Ju-Sun Kim
MYMeesun Yoon
Meesun Yoon
JLJe-Jung Lee
Je-Jung Lee
MSMyung Geun Shin
Myung Geun Shin
DCDuck Cho
Duck Cho

31 October 2008 in Leukemia Research
Verified
Journal Article
Closed access
MSMyung Geun Shin
Myung Geun Shin
HCHyun-Woo Choi
Hyun-Woo Choi
HKHye-Ran Kim
Hye-Ran Kim
MKMi-Ji Kim
Mi-Ji Kim
HBHee-Jo Baek
Hee-Jo Baek
DRDong-Wook Ryang
Dong-Wook Ryang

16 March 2021 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
SMSo Jung Moon
So Jung Moon
HBHee Jo Baek
Hee Jo Baek
BKBo Ram Kim
Bo Ram Kim
WPWoo Jin Park
Woo Jin Park
JKJoheon Kim
Joheon Kim
HKHoon Kook
Hoon Kook
Congenital hepatic hemangioma (CHH) is a common benign vascular tumor of the liver, seen in infancy. The clinical manifestations vary from incidental findings to life-threatening complications. The authors present here a case of an infant with massive CHH who developed systemic hypertension because of compression of the right renal artery by the CHH and did not respond to other lines of treatment. After sirolimus therapy, the CHH size decreased and antihypertensive drugs were no longer necessary. In a critical situation, if the embolization and/or steroids do not seem to control the situation, then adding sirolimus may be considered as secondary therapy with good additive effects.